Cost-Effectiveness of Hybrid PET/CT for Staging of Non–Small Cell Lung Cancer

Although the diagnostic effectiveness of integrated PET/CT for staging of non–small cell lung cancer (NSCLC) has already been proven, it remains to be determined if tumor staging with combined metabolic and anatomic imaging is also cost-effective. The objective of this study was to evaluate from a payers’ perspective the cost-effectiveness of staging NSCLC with CT alone (representing the mainstay diagnostic test) and with integrated PET/CT....